New combo therapy tested for Tough-to-Treat cancers
NCT ID NCT05091346
Summary
This study tested the safety and effectiveness of a new drug, E7386, combined with an existing immunotherapy (pembrolizumab) for people with advanced melanoma, liver cancer, or colorectal cancer that had worsened after prior treatments. The first part checked for side effects and determined the best dose. The second part measured how many patients' tumors shrank or disappeared with the combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barbara Ann Karmanos Cancer Center
Detroit, Michigan, 48201, United States
-
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
-
Chiba University Hospital
Chiba, Japan
-
Clínica Universidad de Navarra
Pamplona, Navarre, Spain
-
Consorcio Hospital General Universitario de Valencia
Valencia, Spain
-
Florida Cancer Specialists
Fort Myers, Florida, 33916, United States
-
Hospital Clinic de Barcelona
Barcelona, Spain
-
Hospital Clínico San Carlos
Madrid, Calle Profesor Martín Lagos, Spain
-
Hospital General Universitario Gregorio Maranon
Madrid, Spain
-
Hospital Regional Universitario de Malaga
Málaga, Avenida Carolos Haya S/n, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, Spain
-
Hospital Universitario de Badajoz
Badajoz, Spain
-
Hospital Universitario de la Paz
Madrid, Spain
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Imperial College London - Hammersmith Hospital
London, United Kingdom
-
Kindai University Hospital
Ōsaka-sayama, Japan
-
Kurume University Hospital
Fukuoka, Japan
-
National Cancer Center Hospital
Chūōku, Japan
-
National Cancer Center Hospital East
Kashiwa, Japan
-
Osaka Metropolitan University Hospital
Osaka, Japan
-
Providence Medical Center Institute Franz Clinic
Portland, Oregon, 97213, United States
-
Royal Free Hospital NHS Foundation Trust
London, United Kingdom
-
Rutgers cancer Institute of NJ
New Brunswick, New Jersey, 08901, United States
-
SCRI Florida Cancer Specialists East
West Palm Beach, Florida, 33401, United States
-
Sapporo-Kosei General Hospital
Sapporo, Japan
-
Shizuoka Cancer Center Hospital
Shizouka, Japan
-
Tennessee Oncology PPLC
Nashville, Tennessee, 37203, United States
-
The Christie NHS Foundation Trust
Manchester, United Kingdom
-
Toranomon Hospital
Tokyo, Japan
-
University of California, Irvine Health
Orange, California, 92868, United States
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
Winship Cancer Institute
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.